Pilot clinical trial of 18F-fluorodeoxyglucose positron-emission mammography in the surgical management of breast cancer.

Am J Surg 2005 Oct;190(4):628-32

The Breast Center, Anne Arundel Health Systems, 2002 Medical Parkway, Suite 120, Annapolis, MD 21401, USA.

Background: High-resolution positron-emission mammography (PEM) is a new device, which allows the imaging of breast tissue. A prospective study was performed to assess the accuracy of PEM in newly diagnosed breast cancer patients.

Methods: In a prospective multicenter study, 44 women with confirmed breast cancers were imaged with a high-resolution PEM scanner (Naviscan PET Systems, Rockville, MD) with 18F-fluorodeoxyglucose. The images were blindly evaluated and were compared with final pathology.

Results: The majority of the index lesions were seen on PEM (89%, 39/44). PEM detected 4 of 5 incidental breast cancers, 3 of which were not seen by any other imaging modalities. Of 19 patients undergoing breast-conserving surgery, PEM correctly predicted 6 of 8 (75%) patients with positive margins and 100% (11/11) with negative margins.

Conclusion: The current PEM device shows promise in detecting breast malignancies and may assist in the planning of adequate partial mastectomy procedures to better ensure negative margins.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.amjsurg.2005.06.029DOI Listing
October 2005
39 Reads

Publication Analysis

Top Keywords

positron-emission mammography
8
breast cancer
8
breast cancers
8
pem device
8
pem
7
breast
6
89% 39/44
4
pem 89%
4
patients undergoing
4
lesions pem
4
39/44 pem
4
pem detected
4
incidental breast
4
cancers imaging
4
detected incidental
4
majority lesions
4
modalities patients
4
imaging modalities
4
final pathologyresults
4
scanner naviscan
4

Similar Publications